Download PDF
TumorDiagnostik & Therapie 2021; 42(01): 45-49
DOI: 10.1055/a-1332-8347
Schwerpunkt Gynäkologische Tumoren

Aktuelle Entwicklungen in der Therapie des Endometrium- und Zervixkarzinoms

Louisa Proppe
,
Achim Rody
,
Lars C. Hanker
› Further Information
Also available at
    Permissions and Reprints

Neue medikamentöse Therapieoptionen durch Immuncheckpoint-Inhibitoren können signifikante Verbesserungen von Lebensqualität und -quantität ermöglichen, bergen aber auch Risiken neuer und teils erheblicher Nebenwirkungen. Darüber hinaus gibt es wichtige aktuelle Veränderungen in der operativen Therapie des frühen Endometrium- und Zervixkarzinoms.

Publication History

Article published online:
28 January 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 RKI Zentrum für Krebsregisterdaten. Krebs in Deutschland – Gebärmutterkörper 2015.
    PubMedGoogle Scholar
  • 2 Creutzberg CL, van Putten WL, Koper E. et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet 2000; 355: 1404-1411
    CrossrefPubMedGoogle Scholar
  • 3 Kommoss S, McConechy MK, Kommoss F. et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol 2018; 29: 1180-1188
    CrossrefPubMedGoogle Scholar
  • 4 Carter J, Huang HQ, Armer J. et al. GOG 244 – The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function. Gynecol Oncol 2020; DOI: 10.1016/j.ygyno.2019.09.027.
    CrossrefPubMedGoogle Scholar
  • 5 Volpi L, Sozzi G, Capozzi VA. et al. Long term complications following pelvic and para-aortic lymphadenectomy for endometrial cancer, incidence and potential risk factors: a single institution experience. Int J Gynecol Cancer 2019; 29: 312-319
    CrossrefPubMedGoogle Scholar
  • 6 Rossi EC, Kowalski DL, Scalici J. et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol 2017; 18: 384-392
    CrossrefPubMedGoogle Scholar
  • 7 Persson J, Salehi S, Bollino M. et al. Pelvic Sentinel lymph node detection in High-Risk Endometrial Cancer (SHREC-trial) – the final step towards a paradigm shift in surgical staging. Eur J Cancer 2019; 116: 77-85
    CrossrefPubMedGoogle Scholar
  • 8 Ignatov A, Papathemelis T, Ivros S. et al. Comparison of survival of patients with endometrial cancer undergoing sentinel node biopsy alone or systematic lymphadenectomy. Arch Gynecol Obstet 2020; 302: 995-1000
    CrossrefPubMedGoogle Scholar
  • 9 Holloway RW, Abu-Rustum NR, Backes FJ. et al. Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol 2017; 146: 405-415
    CrossrefPubMedGoogle Scholar
  • 10 Matei D, Filiaci V, Randall ME. et al. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. N Engl J Med 2019; 380: 2317-2326
    CrossrefPubMedGoogle Scholar
  • 11 Oaknin A, Duska LR, Sullivan RJ. et al. Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-h and MSS endometrial cancer. Gynecol Oncol 2019; 154 (Suppl. 01) 17
    CrossrefPubMedGoogle Scholar
  • 12 Makker V, Taylor MH, Aghajanian C. et al. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. J Clin Oncol 2020; 38: 2981-2992
    CrossrefPubMedGoogle Scholar
  • 13 Hanker L, Mirza MR, Coleman RL. et al ENGOT-EN6/GOG-3031/NSGO-RUBY: Eine randomisierte, doppelt-blinde, multizentrische Phase III Studie mit Dostarlimab + Carboplatin-Paclitaxel versus Placebo + Carboplatin-Paclitaxel in rezidiviertem oder primär fortgeschrittenem Endometriumkarzinom (EC). DGHO Jahrestagung 2020; Abstract 277
    PubMedGoogle Scholar
  • 14 Musacchio L, Caruso G, Pisano C. et al. PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives. Cancer Managem Res 2020; 12: 6123-6135
    CrossrefPubMedGoogle Scholar
  • 15 Ramirez PT, Frumovitz M, Pareja R. et al. Phase III randomized trial of laparoscopic or robotic versus abdominal radical hysterectomy in patients with early-stage cervical cancer: LACC Trial. Gynecol Oncol 2018; 149 (Suppl. 01) DOI: 10.1016/j.ygyno.2018.04.552.
    CrossrefPubMedGoogle Scholar
  • 16 S3-Leitlinie Diagnostik und Therapie Zervixkarzinom. 2014; Registernummer 032-033OL
    PubMedGoogle Scholar
  • 17 Lecuru FR, McCormack M, Hillemanns P. et al. SENTICOL III: an international validation study of sentinel node biopsy in early cervical cancer. A GINECO, ENGOT, GCIG and multicenter study. Int J Gynecol Cancer 2019; 29: 829-834
    CrossrefPubMedGoogle Scholar
  • 18 Cibula D, Dusek J, Jarkovsky J. et al. A prospective multicenter trial on sentinel lymph node biopsy in patients with early-stage cervical cancer (SENTIX). Int J Gynecol Cancer 2019; 29: 212-215
    CrossrefPubMedGoogle Scholar
  • 19 Gupta S, Maheshwari A, Parab P. et al. Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial. J Clin Oncol 2018; 36: 1548-1555
    CrossrefPubMedGoogle Scholar
  • 20 Kenter G, Greggi S, Vergote I. et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer, EORTC 55994. J Clin Oncol 2019; 37 (Suppl. 15) 5503-5503
    CrossrefPubMedGoogle Scholar
  • 21 Tewari KS, Sill MW, Penson RT. et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 2017; 390: 1654-1663
    CrossrefPubMedGoogle Scholar
  • 22 Redondo A, Colombo N, McCormack M. et al. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer. Gynecol Oncol 2020; 159: 142-149
    CrossrefPubMedGoogle Scholar
  • 23 Marabelle A, Le DT, Ascierto PA. et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 2020; 38: 1-10
    CrossrefPubMedGoogle Scholar
  • 24 Naumann RW, Hollebecque A, Meyer T. et al. Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. J Clin Oncol 2019; 37: 2825-2834
    CrossrefPubMedGoogle Scholar
  • 25 Grau JF, Farinas-Madrid L, Oaknin A. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030). Int J Gynecol Cancer 2020; 30: 139-143
    CrossrefPubMedGoogle Scholar
  • 26 Lorusso D, Colombo N, Coleman RL. et al. ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer. J Clin Oncol 2020; 38 (Suppl. 15) TPS6096-TPS6096
    CrossrefPubMedGoogle Scholar